Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Tan EX, et al. Among authors: nakajima a. Metabolism. 2022 Jan;126:154911. doi: 10.1016/j.metabol.2021.154911. Epub 2021 Oct 12. Metabolism. 2022. PMID: 34648769 Free article.
Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue.
Yoneda M, Iwasaki T, Fujita K, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S, Wada K, Saito S, Terauchi Y, Nakajima A. Yoneda M, et al. Among authors: nakajima a. Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21. doi: 10.1111/j.1530-0277.2006.00281.x. Alcohol Clin Exp Res. 2007. PMID: 17331160
Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.
Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Fujita K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama S, Wada K, Nakajima A. Yoneda M, et al. Among authors: nakajima a. Liver Int. 2009 Aug;29(7):1078-85. doi: 10.1111/j.1478-3231.2009.01988.x. Epub 2009 Mar 3. Liver Int. 2009. PMID: 19302184
Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study.
Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Imajo K, Sakaguchi T, Atsukawa K, Sawabe A, Kanesaki A, Takahashi H, Abe Y, Inamori M, Kobayashi N, Kubota K, Ueno N, Nakajima A. Kirikoshi H, et al. Among authors: nakajima a. BMC Gastroenterol. 2009 Apr 30;9:29. doi: 10.1186/1471-230X-9-29. BMC Gastroenterol. 2009. PMID: 19405938 Free PMC article.
Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis.
Yoneda M, Fujita K, Imajo K, Mawatari H, Kirikoshi H, Saito S, Nakajima A. Yoneda M, et al. Among authors: nakajima a. J Gastroenterol. 2011 Mar;46(3):415-6; author reply 417. doi: 10.1007/s00535-010-0356-8. Epub 2010 Dec 22. J Gastroenterol. 2011. PMID: 21181211 No abstract available.
Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis.
Fujita K, Imajo K, Shinohara Y, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Abe Y, Inamori M, Shimamura T, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Fujita K, et al. Among authors: nakajima a. J Pharmacol Sci. 2011;115(3):270-3. doi: 10.1254/jphs.10r14fm. Epub 2011 Feb 22. J Pharmacol Sci. 2011. PMID: 21350309 Free article. Review.
2,136 results